国产99热精品_欧美疯狂做受xxxx猛交_婷婷在线网站_日韩无遮挡毛片_欧美高清momspuss_欧美激情福利

RXi Pharmaceuticals  
RNAi技術平臺的創新療法

RXi Pharmaceuticals Corporation (OTC: RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, next-generation RNAi platform. Therapeutics that use RNA interference, or “RNAi,” have great promise because of their ability to “silence,” or down-regulate, the expression of a specific gene that may be overexpressed in a disease condition. Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, RXi’s first RNAi product candidate, RXI-109, entered into RXi’s first human clinical trial in 2012. RXI-109 targets connective tissue growth factor (CTGF), a key regulatory of fibrosis and scar formation, and is initially being developed to reduce or inhibit scar formation in the skin following surgery.

Specialties
Development of RNAi based therapeutics, RXI-109-lead candidate in Phase 1 for the reduction of dermal scarring, RXi Next Generation Therapeutic Platform: sd-rxRNA?, Multi-layered patent portfolio